Peptide Profiles — 2026-05-15
One of the most common questions in reta research is the timeline — what changes when, and what magnitude of effect should researchers expect at each phase of a protocol. This article synthesizes the published Phase 2 dose-response and time-course data (Jastreboff et al., NEJM 2023, and follow-up reports) into a practical month-by-month expectation map.
Researcher special: code WELCOME at checkout unlocks 35% off Reta 10mg, Reta 20mg, the Metabolic Stack, and bacteriostatic water. Every vial ships with a batch-matched COA at 99%+ HPLC purity.
This is a timeline-focused piece. For mechanism and side-effect detail, see reta benefits and side effects research. For dosing math, see the reta beginner dosing protocol.
The reference dataset for this timeline is the Phase 2 obesity trial reported by Jastreboff et al. (NEJM, June 2023). Key parameters:
Endpoints tracked at 4, 12, 24, 36, and 48 weeks. The data points below come from the published mean values at each timepoint, primarily for the 8 mg and 12 mg arms (the doses most relevant to research protocols).
Most reta research protocols start with low-dose titration to minimize GI side effects. Typical starting dose is 2 mg/week, escalated every 2–4 weeks.
What happens at this stage: - Appetite suppression begins almost immediately — most subjects report reduced hunger within 3–7 days of the first dose - Average weight change at week 4: −2% to −4% of baseline body weight - Glycemic improvements emerge: fasting glucose drops, sometimes within 1–2 weeks - GI side effects (nausea, occasional vomiting) are most prominent during dose escalations - Heart rate may increase by 3–7 bpm at rest
Common research-protocol mistakes at this phase: - Escalating too fast → preventable GI burden - Expecting visible body-composition change → the early phase is mostly fluid and early appetite-driven losses - Concluding "it's not working" → see the reta beginner protocol for why the first 4 weeks are mostly setup
By week 8–12, most subjects have reached or are approaching their target dose. The weight-loss curve steepens.
Phase 2 mean weight reduction by week 12: - 4 mg arm: −7% of baseline - 8 mg arm: −10% to −12% - 12 mg arm: −12% to −15%
Other changes in this window: - Waist circumference reduces in proportion to total weight - Fasting insulin drops, often by 30–40% - HbA1c trajectory becomes clear (typically −0.5 to −1.0 percentage points by week 12 in diabetic models) - Blood pressure (especially systolic) drops by 4–8 mmHg - Triglycerides drop substantially (often −30% to −40%) - Heart rate plateaus at the elevated level seen in week 4
What researchers typically notice clinically: - Subjects report sustained appetite suppression rather than the early-phase variable effect - Energy levels stabilize after the GI-symptom phase - Body-composition changes become visible (subjective, not yet DEXA-measurable for most subjects)
This is the period during which the bulk of body-composition change occurs in the Phase 2 dataset. Subjects are typically at full target dose, and weight loss runs at a steady ~1–1.5% per week at the 8–12 mg doses.
Phase 2 mean weight reduction by week 24: - 4 mg arm: −12% to −14% - 8 mg arm: −17% to −19% - 12 mg arm: −19% to −22%
Body-composition specifics (DEXA substudies): - Fat mass accounts for ~80–85% of the total weight loss - Lean mass loss is present but proportional — broadly what a 20% energy deficit would produce - Visceral fat reduces more than subcutaneous fat (proportionally similar to tesamorelin's preferential VAT effect, though driven by a different mechanism)
Metabolic changes: - Liver fat (in MASLD substudies) drops 60–80% by week 24 - Insulin sensitivity (HOMA-IR) improves 50–70% - Lipid panel improvements are largely complete by this point
This is the phase where reta visibly differentiates itself from sema and triz on the weight-loss curve. The third receptor (glucagon) appears to drive a steeper trajectory once metabolic flexibility has been re-established.
For the head-to-head data, see reta vs Ozempic research and reta vs Wegovy research.
The weight-loss curve continues but begins to decelerate. The 48-week Phase 2 endpoints:
A meaningful share of subjects in the 12 mg arm exceeded 30% body-weight loss by week 48 — unprecedented for a single peptide compound.
Curve shape: - Loss rate slows from ~1.5%/week at weeks 12–24 to ~0.5%/week by weeks 36–48 - A subset of subjects approach a true plateau by week 48; most are still trending downward at slower rates - Lean-mass loss continues to track total loss roughly proportionally — no evidence of accelerated muscle loss in extended exposure
Side-effect profile in extended exposure: - GI symptoms attenuate substantially after the dose-escalation phase - New side-effect emergence at this stage is rare - Mild transient transaminase elevations (when present) tend to occur during the rapid-loss phase rather than the plateau approach
The Phase 2 dataset stops at 48 weeks. The Phase 3 program (TRIUMPH) is filling in the longer-term picture as readouts arrive. Key open questions:
For the broader research context, see what is reta.
For researchers planning a reta protocol, the timeline implies:
| Protocol length | Reasonable endpoints |
| 4 weeks | Tolerability, titration, early metabolic signals (insulin, glucose) |
| 12 weeks | Initial weight change, lipid panel, blood pressure, A1c trajectory |
| 24 weeks | Substantial body-composition change, MASLD endpoints, HOMA-IR full effect |
| 48 weeks | Full Phase-2-comparable endpoints |
| 72+ weeks | Durability and maintenance research (limited published precedent) |
Protocols shorter than 12 weeks generally don't capture the full effect signal. Protocols longer than 48 weeks are research-novel territory.
A standard 24-week reta research protocol at the 12 mg endpoint:
Total peptide needed: approximately 200 mg (varies with titration speed). At the Reta 20mg vial size, that's 10 vials. At the Reta 10mg size, that's 20.
For exact reconstitution and unit-syringe math, see the reta dosing guide.
Code WELCOME at checkout unlocks 35% off Reta 10mg, Reta 20mg, the Metabolic Stack, and bacteriostatic water. Every vial ships with a batch-matched COA showing 99%+ HPLC purity — critical for a 24-week protocol where dose-response endpoints depend on consistent batch potency.
Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.